Choosing first treatment for T-cell lymphoma: diagnosis, regimen and response planning

At the first treatment discussion, patients often ask which medicine is strongest, whether transplantation is inevitable and how soon treatment should begin. For T-cell lymphoma, the complete diagnosis has to come first. A nodal mature T-cell lymphoma, skin-limited disease, an NK/T-cell lymphoma and a lymphoblastic malignancy do not share one standard prescription. This article focuses on the initial discussion for adults with systemic mature T-cell lymphoma and identifies situations that require a different pathway.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Treatment does not always need to wait for every research-oriented test. It does require adequate information about the disease entity, extent and factors that affect safe drug delivery. If pathology still says that further classification is needed, ask whether the proposed treatment is an urgent measure to stabilise a problem or the intended definitive approach based on an integrated diagnosis.
Some patients with mature T-cell lymphoma who respond to initial treatment are considered for autologous stem cell transplantation as consolidation. Their own collected cells support recovery after intensive treatment; this is not the same as receiving a donor immune system. Suitability depends on entity, risk, response, organ function and patient preference. An automatic rule for every patient in a first remission, including every ALK-positive ALCL case, would ignore these distinctions. Hübel et al.: Other B- and T-Aggressive Lymphomas, EBMT Handbook 2024
Ask at the outset when clinical review, laboratory tests or imaging are planned and which symptoms should bring that review forward. Feeling better provides useful information but does not replace a formal response assessment. Conversely, one laboratory flag or an uncertain scan finding should not lead a patient to declare treatment failure without interpretation. Lymphoma response criteria help organise the comparison with baseline findings. Cheson et al.: Lugano classification for lymphoma evaluation and response

Quick answer

Full guide

Establish what is already known well enough to act on

Treatment does not always need to wait for every research-oriented test. It does require adequate information about the disease entity, extent and factors that affect safe drug delivery. If pathology still says that further classification is needed, ask whether the proposed treatment is an urgent measure to stabilise a problem or the intended definitive approach based on an integrated diagnosis.

The 2025 ESMO–EHA guideline organises recommendations by mature T-cell and NK-cell entity. In an emergency, clinicians balance stabilisation and tissue diagnosis. When the patient is stable, review of information that would change the regimen may be possible first. An overseas appointment should not prompt an unsupervised interruption of urgent care, nor should an incompletely classified case be presented as having only one unquestionable regimen. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Why BV-CHP is often discussed for systemic ALCL

Brentuximab vedotin is a CD30-directed antibody-drug conjugate. BV-CHP combines it with cyclophosphamide, doxorubicin and prednisone. ECHELON-2 compared this approach with CHOP and reported sustained benefit at longer follow-up in its study population, most of whom had systemic anaplastic large cell lymphoma. Discussion should connect that evidence to the individual's entity, ALK status and clinical circumstances. Horwitz et al.: ECHELON-2 five-year results

Vincristine, which appears in CHOP, is not retained in BV-CHP. Patients should not combine the two lists on the assumption that an extra drug will improve the regimen. Existing numbness, walking difficulty or diabetic nerve problems should be documented before treatment so that the team can consider neurological toxicity and monitoring. The actual prescription, including any subsequent adjustment, comes from the treating team.

FDA approved this combination in 2018 for the specified previously untreated systemic ALCL and CD30-expressing PTCL adult populations in the United States. That is a US regulatory statement. China's National Health Commission 2025 drug guidance distinguishes domestic indications from uses approved elsewhere. A hospital in China needs to check the current Chinese label and later updates rather than infer local approval from the US announcement. FDA: initial approval of brentuximab vedotin plus chemotherapy for untreated CD30-expressing PTCL 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

PTCL-NOS and TFH-derived disease need more than a CD30 result

For nodal PTCL-NOS and follicular helper T-cell lymphomas, CHOP or an appropriate CHOP-like regimen remains an important first-line framework in the guideline. Selected patients may discuss CHOEP, which adds etoposide, with attention to its additional burden. Youth alone does not mandate intensification, and older age alone should not end consideration of active treatment. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

CD30 expression can lead to discussion of BV-containing treatment, but small non-ALCL subgroups in ECHELON-2 should not be described as separate large confirmatory trials for each subtype. Regional recommendations, regulatory scope and interpretation of limited evidence can differ. When recommendations conflict, ask whether each is based on a randomised comparison, a subgroup finding or an individualised clinical judgement. Horwitz et al.: ECHELON-2 five-year results

Heart, liver or kidney problems and functional limitations may change what can be delivered. NCI's PTCL summary separates entities and reflects the limited evidence in some areas. A lower-burden strategy is not automatically an abandonment of care; it may be the most feasible way to pursue disease control in a particular situation. The intended aim and trade-offs should be recorded clearly. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

Some diagnoses lead away from the usual nodal PTCL discussion

Certain early cutaneous T-cell lymphomas can be considered for skin-directed treatment. The need for systemic therapy depends on the relevant stage and response. Referral from dermatology to haematology does not itself mean that nodal PTCL combination chemotherapy should start. Both teams should establish that they are discussing the same entity and disease stage. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment

NK/T-cell lymphoma often needs a separate discussion involving radiotherapy and non-anthracycline, asparaginase-containing strategies, with differences between localised and more extensive disease. Lymphoblastic malignancy uses its corresponding framework. HTLV-1-associated adult T-cell leukaemia/lymphoma, specialised intestinal entities and implant-associated ALCL should also retain their complete names in transfer documents. Losing those words can lead to a discussion about the wrong treatment population. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

Discuss possible consolidation early without making it inevitable

Some patients with mature T-cell lymphoma who respond to initial treatment are considered for autologous stem cell transplantation as consolidation. Their own collected cells support recovery after intensive treatment; this is not the same as receiving a donor immune system. Suitability depends on entity, risk, response, organ function and patient preference. An automatic rule for every patient in a first remission, including every ALK-positive ALCL case, would ignore these distinctions. Hübel et al.: Other B- and T-Aggressive Lymphomas, EBMT Handbook 2024

An early transplant consultation can clarify assessment, collection and practical requirements without committing the patient before response is known. Ask what response would support proceeding and what complications would lead to reassessment. Allogeneic transplantation involves donor cells and different biological benefits and hazards; the shared word transplant does not make the procedures interchangeable.

NCI's transplant information distinguishes transplant types, conditioning and recovery. Patients can use that framework to prepare questions about caregiving, fertility, infection and care after returning home, then obtain an individual plan. Availability of continuing support matters to implementation and should be addressed before cell collection rather than after it. NCI: Stem Cell Transplants in Cancer Treatment

Supportive care belongs in the first-cycle plan

Provide a complete list of prescriptions, over-the-counter products and supplements, along with infection history, allergies, transfusion problems and current symptoms. The proposed regimen determines appropriate screening and organ assessment. Clinicians also consider early risks such as tumour lysis. It is reasonable to ask what action would follow an abnormal result rather than view pretreatment tests as a generic package.

Low neutrophil counts can increase infection risk. Preventive medicines, growth-factor support and fever instructions should be tailored to the treatment and patient. NCI stresses that infection during cancer treatment may require urgent attention. Obtain a contact route and clear instructions for fever before leaving the hospital. Temporary relief after an antipyretic does not establish that the underlying problem is safe, and leftover antibiotics should not replace assessment. NCI: Infection and Neutropenia during Cancer Treatment

Antiemetic treatment, mouth care and nutrition can also influence whether a planned course is deliverable. Chemotherapy may include intravenous and home-administered medicines, and the recovery interval is part of a cycle. The dates of oral steroids or other tablets should appear on the written schedule. An infusion finishing does not necessarily mean every component of that cycle has finished. NCI: Chemotherapy to Treat Cancer

Bring up fertility and practical support before the first dose

If future parenthood matters, raise it early. The 2025 ASCO fertility-preservation update supports timely discussion and referral for assessment. Available methods depend on the person's circumstances, disease urgency and treatment. No method guarantees a future pregnancy, and medically necessary treatment should not be delayed independently while pursuing a preservation procedure. The relevant specialists need to coordinate that decision. ASCO: Fertility Preservation in People With Cancer, 2025 guideline update

Practical arrangements can be specific: who attends appointments, who keeps track of oral medicines, where urgent care is available at night and who contacts the team if a visit cannot be attended. International patients planning initial treatment in China should confirm the receiving service and support between cycles before travel. Airline dates should not force shortened recovery or omitted checks. Changes to treatment also need to be reflected in translated records and the current medicine list.

Know how response will be assessed

Ask at the outset when clinical review, laboratory tests or imaging are planned and which symptoms should bring that review forward. Feeling better provides useful information but does not replace a formal response assessment. Conversely, one laboratory flag or an uncertain scan finding should not lead a patient to declare treatment failure without interpretation. Lymphoma response criteria help organise the comparison with baseline findings. Cheson et al.: Lugano classification for lymphoma evaluation and response

The CHEMO-T PET substudy provides evidence for imaging assessment in PTCL and shows that PET and marrow findings need not completely agree. If an interim result raises concern, ask whether review or additional evidence is needed and what supports a treatment change. A test being associated with prognosis is not permission to adjust drugs without the treating team. CHEMO-T investigators: PET/CT substudy in peripheral T-cell lymphoma, 2025

The initial plan should be a document that can be updated: why the regimen was chosen, the intended schedule, supportive measures, assessment points and conditions for discussing the next step. New pathology, substantial toxicity or inadequate response may justify revision. Recording the reason allows the patient and any receiving team to understand the decision instead of treating every change as an unexplained reversal.